Lupin Dental Raises €15M Series A for Robotic Dentistry

Lupin Dental, a French innovator in dental automation, has successfully closed a €15 million Series A funding round. The significant capital infusion was spearheaded by Fynveur, which contributed €10 million, demonstrating strong conviction in the company's technological advancements. Existing stakeholders and additional private investors also participated, bolstering the round. Further financial backing was secured through a loan facility provided by Bpifrance.

This funding marks a pivotal moment for the Montpellier-based startup, founded in 2019 by dental pioneers Dr. Galip Gürel and Dr. Stefen Koubi. The investment will fuel the acceleration of their mission to revolutionize dental procedures through sophisticated robotic solutions. Fynveur, alongside its strategic advisor Invus, will actively support Lupin Dental, with Invus also taking a seat on the company's board, signaling a deep commitment to guiding the startup's growth trajectory.

Lupin Dental is developing the Lupin Robotic System, a supervised automated platform designed to enhance precision in minimally invasive dental preparations, particularly for aesthetic veneers. The system integrates advanced software for smile design and treatment planning, which then directs a robotic workstation to execute precise tooth preparation. This approach aims to elevate procedural accuracy, streamline clinical workflows, and ultimately improve patient outcomes in complex aesthetic dentistry, a segment experiencing growing demand globally.

The company has recently achieved key regulatory milestones, including obtaining UKCA certification for the Lupin Robotic System, paving the way for its commercialization in Great Britain. This follows earlier regulatory clearance in India. While not yet approved for the US or EU markets, these certifications represent significant steps toward broader market access. The dental robotics market, though nascent, is projected for substantial growth as practitioners seek enhanced efficiency and predictability in treatments.

The strategic expansion of Lupin Dental's reach will involve forging partnerships with leading academic and medical institutions, as well as dental professionals and Dental Service Organizations (DSOs). This collaborative strategy is crucial for driving the widespread adoption of their innovative robotic technology. The company has also recently strengthened its leadership, appointing industry veteran Michel Mayer as Chairman and Philippe Veran, founder of Biotech Dental, to its board, bringing extensive experience in semiconductors and dental technology respectively.

This Series A funding positions Lupin Dental to further refine its technology, scale its operations, and navigate the complex regulatory pathways toward global commercialization. The investment underscores the increasing investor interest in medtech innovations that promise to enhance patient care and procedural efficacy within the dental sector.